{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T02:37:02Z","timestamp":1785897422162,"version":"3.56.0"},"reference-count":111,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"NCI","doi-asserted-by":"publisher","award":["R01CA197792"],"award-info":[{"award-number":["R01CA197792"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"NCI","doi-asserted-by":"publisher","award":["R21CA234701"],"award-info":[{"award-number":["R21CA234701"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014228","name":"Duke Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014228","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology &amp; Therapeutics"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.pharmthera.2021.108007","type":"journal-article","created":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T03:02:38Z","timestamp":1632711758000},"page":"108007","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["Chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma"],"prefix":"10.1016","volume":"232","author":[{"given":"Taewoong","family":"Choi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yubin","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2021.108007_bb0005","doi-asserted-by":"crossref","first-page":"16014","DOI":"10.1038\/mto.2016.14","article-title":"CAR models: Next-generation CAR modifications for enhanced T-cell function","volume":"3","author":"Abate-Daga","year":"2016","journal-title":"Molecular Therapy\u2014Oncolytics"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0010","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1158\/1535-7163.MCT-17-1097","article-title":"Strategies to address chimeric antigen receptor tonic signaling","volume":"17","author":"Ajina","year":"2018","journal-title":"Molecular Cancer Therapeutics"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0015","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1182\/blood-2017-08-802926","article-title":"Antitumor activity of CAR-T cells targeting the intracellular oncoprotein WT1 can be enhanced by vaccination","volume":"132","author":"Akahori","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0020","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1182\/blood-2016-04-711903","article-title":"T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma","volume":"128","author":"Ali","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0025","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1182\/blood-2020-140410","article-title":"Updated results from the phase I CRB-402 study of anti-Bcma CAR-T cell therapy bb21217 in patients with relapsed and refractory multiple myeloma: Correlation of expansion and duration of response with T cell phenotypes","volume":"136","author":"Alsina","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0030","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1158\/2326-6066.CIR-18-0307","article-title":"Phase I trial of autologous CAR T cells targeting NKG2D ligands in patients with AML\/MDS and multiple myeloma","volume":"7","author":"Baumeister","year":"2019","journal-title":"Cancer Immunology Research"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0035","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1080\/14712598.2018.1544240","article-title":"CD38 as an immunotherapeutic target in multiple myeloma","volume":"18","author":"Bonello","year":"2018","journal-title":"Expert Opinion on Biological Therapy"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0040","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1200\/JCO.2018.77.8084","article-title":"T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma","volume":"36","author":"Brudno","year":"2018","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0045","doi-asserted-by":"crossref","first-page":"25764","DOI":"10.18632\/oncotarget.25359","article-title":"Pre-clinical validation of B cell maturation antigen (BCMA) as a target for T cell immunotherapy of multiple myeloma","volume":"9","author":"Bu","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0050","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1158\/1078-0432.CCR-12-2422","article-title":"B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma","volume":"19","author":"Carpenter","year":"2013","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0055","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1084\/jem.20182375","article-title":"Single-cell imaging of CAR T cell activity in vivo reveals extensive functional and anatomical heterogeneity","volume":"216","author":"Cazaux","year":"2019","journal-title":"Journal of Experimental Medicine"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0060","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood-2020-133873","article-title":"A phase 1, first-in-human study of Talquetamab, a G protein-coupled receptor family C group 5 member D (GPRC5D) x CD3 bispecific antibody, in patients with relapsed and\/or refractory multiple myeloma (RRMM)","volume":"136","author":"Chari","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0065","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ccr.2009.08.019","article-title":"Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: A therapeutic target","volume":"16","author":"Chauhan","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0070","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.leukres.2019.04.008","article-title":"Serum B-cell maturation antigen (BCMA) reduces binding of anti-BCMA antibody to multiple myeloma cells","volume":"81","author":"Chen","year":"2019","journal-title":"Leukemia Research"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0075","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.3389\/fimmu.2018.01821","article-title":"Targeting B cell maturation antigen (BCMA) in multiple myeloma: Potential uses of BCMA-based immunotherapy","volume":"9","author":"Cho","year":"2018","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0080","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1172\/JCI126397","article-title":"B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma","volume":"129","author":"Cohen","year":"2019","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0085","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1182\/blood-2020-136985","article-title":"Initial clinical activity and safety of BFCR4350A, a FcRH5\/CD3 T-cell-engaging bispecific antibody, in relapsed\/refractory multiple myeloma","volume":"136","author":"Cohen","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0090","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1182\/blood-2020-142695","article-title":"Phase 1\/2 study of the safety and response of P-BCMA-101 CAR-T cells in patients with relapsed\/refractory (r\/r) multiple myeloma (MM) (PRIME) with novel therapeutic strategies","volume":"136","author":"Costello","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0095","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/jgm.2604","article-title":"Chimeric antigen receptors for T cell immunotherapy: Current understanding and future directions","volume":"14","author":"Curran","year":"2012","journal-title":"The Journal of Gene Medicine"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0100","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/s41591-021-01245-5","article-title":"Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma","volume":"27","author":"Da Vi\u00e0","year":"2021","journal-title":"Nature Medicine"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0105","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1182\/blood-2018-99-115319","article-title":"Clinical predictors of T cell fitness for CAR T cell manufacturing and efficacy in multiple myeloma","volume":"132","author":"Dancy","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0110","series-title":"Am Soc Hematology","first-page":"115","article-title":"CAR-engineered T cells specific for the elotuzumab target SLAMF7 eliminate primary myeloma cells and confer selective fratricide of SLAMF7+ normal lymphocyte subsets","volume":"126","author":"Danhof","year":"2015"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0115","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1158\/2159-8290.CD-18-1314","article-title":"Na\u00efve T-cell deficits at diagnosis and after chemotherapy impair cell therapy potential in pediatric cancers","volume":"9","author":"Das","year":"2019","journal-title":"Cancer Discovery"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0120","doi-asserted-by":"crossref","first-page":"565","DOI":"10.2119\/molmed.2011.00493","article-title":"Flexible targeting of ErbB dimers that drive tumorigenesis by using genetically engineered T cells","volume":"18","author":"Davies","year":"2012","journal-title":"Molecular Medicine"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0197349","article-title":"Feasibility of controlling CD38-CAR T cell activity with a Tet-on inducible CAR design","volume":"13","author":"Drent","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0130","doi-asserted-by":"crossref","first-page":"103964","DOI":"10.1016\/j.cellimm.2019.103964","article-title":"The promise of chimeric antigen receptor (CAR) T cell therapy in multiple myeloma","volume":"345","author":"Feinberg","year":"2019","journal-title":"Cellular Immunology"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0135","series-title":"Cyclic ADP-ribose and NAADP: Structures, metabolism and functions","first-page":"65","article-title":"A natural history of the human CD38 gene","author":"Ferrero","year":"2002"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0140","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/j.1600-065X.2011.01037.x","article-title":"Two signal models in innate immunity","volume":"243","author":"Fontana","year":"2011","journal-title":"Immunological Reviews"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0145","doi-asserted-by":"crossref","first-page":"3154","DOI":"10.1182\/blood-2019-127608","article-title":"Efficacy and safety of CAR-T therapy with safety switch targeting Bcma for patients with relapsed\/refractory multiple myeloma in a phase 1 clinical study","volume":"134","author":"Fu","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0150","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1002\/jcp.25419","article-title":"How chimeric antigen receptor design affects adoptive T cell therapy","volume":"231","author":"Gacerez","year":"2016","journal-title":"Journal of Cellular Physiology"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0155","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.120505","article-title":"Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma","volume":"3","author":"Garfall","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0160","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1182\/blood-2020-138831","article-title":"Updated phase 1 results of Teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in relapsed and\/or refractory multiple myeloma (RRMM)","volume":"136","author":"Garfall","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0165","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/nm.4241","article-title":"T memory stem cells in health and disease","volume":"23","author":"Gattinoni","year":"2017","journal-title":"Nature Medicine"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0170","doi-asserted-by":"crossref","first-page":"785","DOI":"10.3324\/haematol.2016.150896","article-title":"Serum B-cell maturation antigen: A novel biomarker to predict outcomes for multiple myeloma patients","volume":"102","author":"Ghermezi","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0175","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1158\/2326-6066.CIR-20-0118","article-title":"Treatment of multiple myeloma using chimeric antigen receptor T cells with dual specificity","volume":"8","author":"Globerson Levin","year":"2020","journal-title":"Cancer Immunology Research"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0180","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1182\/blood-2017-04-778423","article-title":"SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7(+) normal lymphocytes","volume":"130","author":"Gogishvili","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0185","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1182\/blood-2018-99-117729","article-title":"Fully human Bcma targeted chimeric antigen receptor T cells administered in a defined composition demonstrate potency at low doses in advanced stage high risk multiple myeloma","volume":"132","author":"Green","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0190","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1182\/blood-2018-99-111419","article-title":"Efficacy and safety of P-Bcma-101 CAR-T cells in patients with relapsed\/refractory (r\/r) multiple myeloma (MM)","volume":"132","author":"Gregory","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0195","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.omtm.2018.12.009","article-title":"Engineering and design of chimeric antigen receptors","volume":"12","author":"Guedan","year":"2019","journal-title":"Molecular Therapy - Methods & Clinical Development"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0200","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jocit.2014.11.001","article-title":"CD138-directed adoptive immunotherapy of chimeric antigen receptor (CAR)-modified T cells for multiple myeloma","volume":"2","author":"Guo","year":"2016","journal-title":"Journal of Cellular Immunotherapy"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/jid.2013.521","article-title":"Antibody phage display: Technique and applications","volume":"134","author":"Hammers","year":"2014","journal-title":"The Journal of Investigative Dermatology"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0210","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1182\/blood-2020-140156","article-title":"Two-year follow-up of investigator-initiated phase 1 trials of the safety and efficacy of fully human anti-Bcma CAR T cells (CT053) in relapsed\/refractory multiple myeloma","volume":"136","author":"Hao","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0215","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1182\/blood.V128.22.2127.2127","article-title":"A novel Bcma-specific, centyrin-based CAR-T product for the treatment of multiple myeloma","volume":"128","author":"Hermanson","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0220","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1001\/jamaoncol.2018.4657","article-title":"Accounting for all costs in the total cost of chimeric antigen receptor T-cell immunotherapy-reply","volume":"4","author":"Hernandez","year":"2018","journal-title":"JAMA Oncology"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0225","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nrc2189","article-title":"Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets","volume":"7","author":"Hideshima","year":"2007","journal-title":"Nature Reviews Cancer"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0230","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1182\/blood-2017-07-793760","article-title":"Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy","volume":"131","author":"Hill","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0235","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1177\/2040620718775629","article-title":"Update on the role of lenalidomide in patients with multiple myeloma","volume":"9","author":"Holstein","year":"2018","journal-title":"Therapeutic Advances in Hematology"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0240","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1158\/1078-0432.CCR-07-4246","article-title":"CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma","volume":"14","author":"Hsi","year":"2008","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0245","first-page":"25","article-title":"Clinical results of a multicenter study of the first-in-human dual BCMA and CD19 targeted novel platform Fast CAR-T cell therapy for patients with relapsed\/refractory multiple myeloma","volume":"136","author":"Jiang","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0250","doi-asserted-by":"crossref","first-page":"4435","DOI":"10.1182\/blood-2019-126104","article-title":"Phase 1 trial of the safety and efficacy of fully human anti-Bcma CAR T cells in relapsed\/refractory multiple myeloma","volume":"134","author":"Jie","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0255","doi-asserted-by":"crossref","first-page":"9160","DOI":"10.1158\/0008-5472.CAN-04-0454","article-title":"Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells","volume":"64","author":"Kahlon","year":"2004","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0260","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1158\/1535-7163.MCT-18-1216","article-title":"Anti-GPRC5D\/CD3 bispecific T-cell-redirecting antibody for the treatment of multiple myeloma","volume":"18","author":"Kodama","year":"2019","journal-title":"Molecular Cancer Therapeutics"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0265","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41467-019-14119-9","article-title":"Anti-BCMA chimeric antigen receptors with fully human heavy-chain-only antigen recognition domains","volume":"11","author":"Lam","year":"2020","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0270","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1158\/2643-3230.BCD-20-0020","article-title":"Defining an optimal dual-targeted CAR T-cell therapy approach simultaneously targeting BCMA and GPRC5D to prevent BCMA escape-driven relapse in multiple myeloma","volume":"1","author":"de Larrea","year":"2020","journal-title":"Blood Cancer Discovery"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0275","doi-asserted-by":"crossref","first-page":"7333","DOI":"10.1038\/ncomms8333","article-title":"\u03b3-Secretase directly sheds the survival receptor BCMA from plasma cells","volume":"6","author":"Laurent","year":"2015","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0280","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biology of Blood and Marrow Transplantation"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0285","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1182\/blood-2017-05-781351","article-title":"An APRIL-based chimeric antigen receptor for dual targeting of BCMA and TACI in multiple myeloma","volume":"131","author":"Lee","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0290","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1182\/blood-2019-128468","article-title":"Efficacy and safety of fully human Bcma targeting CAR T cell therapy in relapsed\/refractory multiple myeloma","volume":"134","author":"Li","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0295","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/blood-2018-99-116898","article-title":"T cells expressing anti B-cell maturation antigen chimeric antigen receptors for plasma cell malignancies","volume":"132","author":"Li","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0300","doi-asserted-by":"crossref","first-page":"8013","DOI":"10.1200\/JCO.2019.37.15_suppl.8013","article-title":"Clinical responses and pharmacokinetics of fully human BCMA targeting CAR T-cell therapy in relapsed\/refractory multiple myeloma","volume":"37","author":"Li","year":"2019","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0305","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.18.02079","article-title":"Cost effectiveness of chimeric antigen receptor T-cell therapy in multiply relapsed or refractory adult large B-cell lymphoma","volume":"37","author":"Lin","year":"2019","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0310","doi-asserted-by":"crossref","first-page":"978","DOI":"10.3324\/haematol.2019.238634","article-title":"Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma","volume":"106","author":"Logue","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0315","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood-2020-136307","article-title":"CARTITUDE-1: Phase 1b\/2 study of ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T cell therapy, in relapsed\/refractory multiple myeloma","volume":"136","author":"Madduri","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0320","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1182\/blood-2020-139192","article-title":"REGN5458, a BCMA x CD3 bispecific monoclonal antibody, induces deep and durable responses in patients with relapsed\/refractory multiple myeloma (RRMM)","volume":"136","author":"Madduri","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0325","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1182\/blood-2018-99-119717","article-title":"Clinical responses and pharmacokinetics of MCARH171, a human-derived Bcma targeted CAR T cell therapy in relapsed\/refractory multiple myeloma: Final results of a phase I clinical trial","volume":"132","author":"Mailankody","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0330","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1182\/blood-2018-99-113548","article-title":"JCARH125, anti-BCMA CAR T-cell therapy for relapsed\/refractory multiple myeloma: Initial proof of concept results from a phase 1\/2 multicenter study (EVOLVE)","volume":"132","author":"Mailankody","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0335","doi-asserted-by":"crossref","first-page":"8504","DOI":"10.1200\/JCO.2020.38.15_suppl.8504","article-title":"Orvacabtagene autoleucel (orva-cel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed\/refractory multiple myeloma (RRMM): Update of the phase 1\/2 EVOLVE study (NCT03430011)","volume":"38","author":"Mailankody","year":"2020","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0340","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1182\/blood-2020-140641","article-title":"Universal: An allogeneic first-in-human study of the anti-Bcma ALLO-715 and the anti-CD52 ALLO-647 in relapsed\/refractory multiple myeloma","volume":"136","author":"Mailankody","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0345","first-page":"1913","article-title":"Development of T-cell therapy by exploiting modified antibodies specific for A2\/NY-ESO-1 for refractory myeloma","author":"Maruta","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0350","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/imcb.12254","article-title":"Chimeric antigen receptor T cell persistence and memory cell formation","volume":"97","author":"McLellan","year":"2019","journal-title":"Immunology and Cell Biology"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0355","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1182\/blood-2020-138839","article-title":"Deep and durable remissions of relapsed multiple myeloma on a first-in-humans clinical trial of T cells expressing an anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) with a fully-human heavy-chain-only antigen recognition domain","volume":"136","author":"Mikkilineni","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0360","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0365","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1182\/blood-2003-06-2043","article-title":"Expression of BCMA, TACI, and BAFF-R in multiple myeloma: A mechanism for growth and survival","volume":"103","author":"Novak","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0370","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.3389\/fimmu.2018.02749","article-title":"Promises and pitfalls in the use of PD-1\/PD-L1 inhibitors in multiple myeloma","volume":"9","author":"Oliva","year":"2018","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0375","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1182\/blood.2019003342","article-title":"A T-cell\u2013redirecting bispecific G-protein\u2013coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma","volume":"135","author":"Pillarisetti","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0380","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/s13238-016-0367-1","article-title":"T-cell receptor-engineered T cells for cancer treatment: Current status and future directions","volume":"9","author":"Ping","year":"2018","journal-title":"Protein & Cell"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0385","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1182\/blood.2019000050","article-title":"\u03b3-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma","volume":"134","author":"Pont","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0390","doi-asserted-by":"crossref","first-page":"3112","DOI":"10.1182\/blood-2019-126689","article-title":"Phase 1 first-in-human study of AUTO2, the first chimeric antigen receptor (CAR) T cell targeting APRIL for patients with relapsed\/refractory multiple myeloma (RRMM)","volume":"134","author":"Popat","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0395","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/s41434-021-00254-w","article-title":"CARAMBA: A first-in-human clinical trial with SLAMF7 CAR-T cells prepared by virus-free sleeping beauty gene transfer to treat multiple myeloma","volume":"28","author":"Prommersberger","year":"2021","journal-title":"Gene Therapy"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0400","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0405","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1172\/JCI86000","article-title":"Clinical responses with T lymphocytes targeting malignancy-associated kappa light chains","volume":"126","author":"Ramos","year":"2016","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0410","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1172\/JCI86000","article-title":"Clinical responses with T lymphocytes targeting malignancy-associated \u03ba light chains","volume":"126","author":"Ramos","year":"2016","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0415","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/nm.3910","article-title":"NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma","volume":"21","author":"Rapoport","year":"2015","journal-title":"Nature Medicine"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0420","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1073\/pnas.77.3.1588","article-title":"Discrete stages of human intrathymic differentiation: Analysis of normal thymocytes and leukemic lymphoblasts of T-cell lineage","volume":"77","author":"Reinherz","year":"1980","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0425","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.jcyt.2018.11.009","article-title":"Manufacturing chimeric antigen receptor T cells: Issues and challenges","volume":"21","author":"Roddie","year":"2019","journal-title":"Cytotherapy"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0430","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1182\/blood-2020-139893","article-title":"Initial results of a phase I study of TNB-383B, a BCMA x CD3 bispecific T-cell redirecting antibody, in relapsed\/refractory multiple myeloma","volume":"136","author":"Rodriguez","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0435","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s13045-020-01001-1","article-title":"Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma","volume":"13","author":"Roex","year":"2020","journal-title":"Journal of Hematology & Oncology"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0440","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1182\/blood-2020-139040","article-title":"Biallelic loss of BCMA triggers resistance to anti-BCMA CAR T cell therapy in multiple myeloma","volume":"136","author":"Samur","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0445","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.ccell.2017.02.002","article-title":"Target expression, generation, preclinical activity, and pharmacokinetics of the BCMA-T cell bispecific antibody EM801 for multiple myeloma treatment","volume":"31","author":"Seckinger","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0450","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1182\/blood-2018-99-116953","article-title":"Initial results from a phase 1 clinical study of bb21217, a next-generation anti Bcma CAR T therapy","volume":"132","author":"Shah","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0455","first-page":"372","article-title":"Mechanisms of resistance to CAR T cell therapy","volume":"16","author":"Shah","year":"2019","journal-title":"Nature Reviews. Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0460","doi-asserted-by":"crossref","first-page":"146","DOI":"10.3389\/fonc.2019.00146","article-title":"Multi targeted CAR-T cell therapies for B-cell malignancies","volume":"9","author":"Shah","year":"2019","journal-title":"Frontiers in Oncology"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0465","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1182\/blood-2018-99-117964","article-title":"Tandom autologous transplantation and combined infusion of CD19 and Bcma-specific chimeric antigen receptor T cells for high risk MM: Initial safety and efficacy report from a clinical pilot study","volume":"132","author":"Shi","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0470","first-page":"7","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA: A Cancer Journal for Clinicians"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0475","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau7746","article-title":"GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells","volume":"11","author":"Smith","year":"2019","journal-title":"Science Translational Medicine"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0480","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/j.ymthe.2018.03.016","article-title":"Development and evaluation of an optimal human single-chain variable fragment-derived BCMA-targeted CAR T cell vector","volume":"26","author":"Smith","year":"2018","journal-title":"Molecular Therapy"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0485","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.18632\/oncotarget.26792","article-title":"Safety and efficacy of targeting CD138 with a chimeric antigen receptor for the treatment of multiple myeloma","volume":"10","author":"Sun","year":"2019","journal-title":"Oncotarget"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0490","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1182\/blood-2007-08-107292","article-title":"Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu","volume":"112","author":"Tai","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0495","series-title":"FDA Approves First Cell-Based Gene Therapy for Adult Patients with Multiple Myeloma","author":"U.S. Food and Drug Administration, C. F. B. E. A. R","year":"2021"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0500","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1182\/blood-2019-124953","volume":"134","author":"Wang","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0505","doi-asserted-by":"crossref","first-page":"16015","DOI":"10.1038\/mto.2016.15","article-title":"Clinical manufacturing of CAR T cells: Foundation of a promising therapy","volume":"3","author":"Wang","year":"2016","journal-title":"Molecular Therapy\u2014Oncolytics"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0510","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/CJI.0000000000000320","article-title":"BCMA-targeting bispecific antibody that simultaneously stimulates NKG2D-enhanced efficacy against multiple myeloma","volume":"43","author":"Wang","year":"2020","journal-title":"Journal of Immunotherapy"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0515","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1049","article-title":"Selecting costimulatory domains for chimeric antigen receptors: Functional and clinical considerations","volume":"8","author":"Weinkove","year":"2019","journal-title":"Clinical & Translational Immunology"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0520","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1001\/jamaoncol.2018.4625","article-title":"Accounting for all costs in the Total cost of chimeric antigen receptor T-cell immunotherapy","volume":"4","author":"Whittington","year":"2018","journal-title":"JAMA Oncology"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0525","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s002620100174","article-title":"Human scFv antibody fragments specific for the epithelial tumour marker MUC-1, selected by phage display on living cells","volume":"50","author":"Wong","year":"2001","journal-title":"Cancer Immunology, Immunotherapy"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0530","doi-asserted-by":"crossref","first-page":"9543","DOI":"10.1073\/pnas.1819745116","article-title":"Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed\/refractory multiple myeloma","volume":"116","author":"Xu","year":"2019","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0535","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/cam4.3624","article-title":"Sequential CD19 and BCMA-specific CAR T-cell treatment elicits sustained remission of relapsed and\/or refractory myeloma","volume":"10","author":"Yan","year":"2021","journal-title":"Cancer Medicine"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0540","first-page":"506","article-title":"Combined infusion of CD19 and Bcma-specific chimeric antigen receptor T cells for RRMM: Initial safety and efficacy report from a clinical pilot study","volume":"130","author":"Yan","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0545","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s13045-018-0677-2","article-title":"Universal CARs, universal T cells, and universal CAR T cells","volume":"11","author":"Zhao","year":"2018","journal-title":"Journal of Hematology & Oncology"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0550","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.jcyt.2017.09.005","article-title":"Closed-system manufacturing of CD19 and dual-targeted CD20\/19 chimeric antigen receptor T cells using the CliniMACS prodigy device at an academic medical center","volume":"20","author":"Zhu","year":"2018","journal-title":"Cytotherapy"},{"key":"10.1016\/j.pharmthera.2021.108007_bb0555","doi-asserted-by":"crossref","first-page":"3921","DOI":"10.1158\/1078-0432.CCR-18-2752","article-title":"Targeting multiple myeloma with AMG 424, a novel anti-CD38\/CD3 bispecific T-cell-recruiting antibody optimized for cytotoxicity and cytokine release","volume":"25","author":"Zuch de Zafra","year":"2019","journal-title":"Clinical Cancer Research"}],"container-title":["Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725821002096?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725821002096?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T22:22:47Z","timestamp":1759011767000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725821002096"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":111,"alternative-id":["S0163725821002096"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2021.108007","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2021.108007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108007"}}